Ipilimumab's success has spurred the development of further antibodies that work in similar ways.

易普利姆玛的成功激励研究人员深入研究有着类似工作机制的抗体。

Ipilimumab's successors have pushed the response rate up while maintaining the long-term benefits.

虽然人数不是很多，但这些病人的反应很强烈。有些人可以存活几年而没有疾病特征。

Ipilimumab locks onto and thus blocks the action of a protein, CTLA-4, which sits on the outer membranes of immune-system cells called T-lymphocytes.

易普利姆玛锁定并抑制CTLA-4的活动，这种蛋白位于T淋巴细胞的细胞膜外层。

Some of these people had previously been treated, unsuccessfully, with ipilimumab, confirming that the two drugs really do work in different ways.

有些人之前接受ipilimumab治疗却没有成效，证明了这两种药物确实有着不同的工作机制。

The treatment of melanoma that started the ball rolling (and which was announced at the society's meeting three years ago) employed a drug called ipilimumab. This belongs to a class known as monoclonal antibodies.

这种黑色素瘤治疗是研究人员在三年前的协会会议上公布的。它使用一种名为易普利姆玛（Ipilimumab）的单克隆抗体药物。

In the original trials of ipilimumab, 11% of patients responded. That might not sound many, but those who did respond often did so strongly—surviving in some cases for years with no evidence of disease.

易普利姆玛在最初进行试验时，有11%的病人对药物产生反应。